Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars
Portfolio Pulse from Vandana Singh
Alnylam Pharmaceuticals announced updated interim results for the Phase 1 study of ALN-APP, an investigational RNAi therapeutic for Alzheimer's disease, developed in collaboration with Regeneron Pharmaceuticals. The single doses of ALN-APP have been well tolerated and showed a rapid and sustained reduction in Alzheimer's-linked proteins. The company's shares soared by 9.62% following the announcement.
July 17, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam's shares soared by 9.62% following the announcement of promising results from the Phase 1 study of ALN-APP.
The positive interim results from the Phase 1 study of ALN-APP, a potential treatment for Alzheimer's disease, have boosted investor confidence in Alnylam, leading to a surge in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regeneron Pharmaceuticals is in collaboration with Alnylam for the development of ALN-APP.
Regeneron's collaboration with Alnylam for the development of ALN-APP, a potential Alzheimer's treatment, could positively impact its reputation and investor sentiment.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50